XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona Inc. wins Summary Judgment against Edge Endo and US Endodontics in Patent Infringement Case

Dentsply Sirona Inc. wins Summary Judgment against Edge Endo and US Endodontics in Patent Infringement Case

CHARLOTTE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), The Dental Solutions Company, today announced that on Tuesday, June 23rd, 2020 the United States District Court for the District of New Mexico, in a ruling by Judge Joseph F. Bataillon, held that EdgeTaper Encore endodontic files sold by US Endodontics and Edge Endo infringe at least three valid claims of patents asserted by Dentsply Sirona Inc.  Judge Bataillon granted Dentsply Sirona’s motion for summary judgment that each of the three patent claims were infringed by EdgeTaper Encore and that Dentsply Sirona’s three patent claims are valid.  The Court also rejected Edge’s request to dismiss Dentsply Sirona’s claim that Edge’s infringement was willful.  A finding of willful infringement allows the Court to award treble damages and attorneys’ fees against an adjudicated infringer.

Dentsply Sirona’s case against Edge and US Endo is scheduled for trial before a jury in Albuquerque, New Mexico beginning on August 17, 2020.  At issue will be Dentsply Sirona’s claims for willful infringement and damages with respect to the three claims that have already been held valid and infringed, as well as Dentsply Sirona’s assertion of infringement with respect to additional patent claims.

About Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 133-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental equipment and dental consumable products under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY. Visit for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

John Sweeney, CFA, IRC

Vice President, Investor Relations



Media:

Marion Par-Weixlberger

Vice President Public Relations & Corporate Communications

T +43 (0) 662 2450-588

EN
24/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

 PRESS RELEASE

Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and...

Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company’s focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Den...

 PRESS RELEASE

Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business F...

Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Si...

 PRESS RELEASE

Dentsply Sirona to Participate in Upcoming Investor Conferences

Dentsply Sirona to Participate in Upcoming Investor Conferences CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 2:35 pm ETBaird Global Healthcare Conference on September 9, 2025, at 1:25 pm ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About ...

 PRESS RELEASE

Dentsply Sirona Reports Second Quarter 2025 Results

Dentsply Sirona Reports Second Quarter 2025 Results Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impactGAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52Executed $550 million debt offeringReaffirmed FY25 outlookLeadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Si...

 PRESS RELEASE

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 Outlook CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the “Board”), has been appointed President and Chief Executive Officer, effective A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch